业绩爆雷！万孚生物净利大降七成

Core Insights - Wanfu Bio (300482) reported a significant decline in revenue and net profit for the first three quarters of 2025, with revenue at 1.69 billion CNY, down 22.52% year-on-year, and net profit at 134 million CNY, down 69.32% year-on-year [1][2]. Financial Performance - For Q3 2025, the company achieved revenue of 445 million CNY, a decrease of 26.66% compared to the same period last year [2]. - The net profit attributable to shareholders for Q3 was -55.46 million CNY, reflecting a decline of 169.21% year-on-year [2]. - The net profit after deducting non-recurring gains and losses was -70.91 million CNY, down 213.09% year-on-year [2]. - The basic and diluted earnings per share for Q3 were both -0.11 CNY, a drop of 168.75% year-on-year [2]. - The net cash flow from operating activities for the year-to-date was 52.71 million CNY, down 69.59% [2]. Company Overview - Wanfu Bio is primarily engaged in the research, production, and sales of biotechnology products, including in vitro diagnostic products, reagents, and related medical devices [3]. Market Performance - As of October 24, 2025, Wanfu Bio's stock price was 21.91 CNY, with a market capitalization of 10.256 billion CNY [4][5].